Skip to main content
. 2023 Feb 1;15(3):918. doi: 10.3390/cancers15030918

Figure 6.

Figure 6

Downregulation and upregulation of RIPK4 do not affect PEBP1 or BRAF/ERK/MEK signaling pathway in melanoma cell lines. (a) Comparison of RIPK4 and PEBP-1 in melanocytes (NHEM), primary melanoma cells (WM115), and metastatic melanoma (WM266.4, A375) using Western blot along with densitometry, n = 3. PANC-1 cells expressed as a positive control. (b,c) Cells were transfected with RIPK4.si1 RNA, RIPK4.si2 RNA, or neg.si RNA and analyzed after 48 h via Western blot. Stable A375-dCas9-VPR cells were transfected with two single sgRNAs targeting RIPK4 (RIPK4.sg1, RIPK4.sg2) or with the negative control (sg neg) and analyzed after 72 h via Western blot. GAPDH is the loading control. (b) RIPK4, P-PEBP1, PEBP1 levels in WM266.4, A375, and A375-dCas9 cells. (c) P-BRAF, P-MEK1/2 and P-ERK1/2. Each bar represents the mean ± SD of 3 biological replicates. * p < 0.05 and ** p < 0.01 were considered significant.